Keywords: Pfizer, Medivation, Dimebon, Alzheimer's, bapineuzumab, solanexumab,
Pfizer/Medivation's Dimebon could generate peak annual sales of $1.5 Billion
Article | 12 January 2010
Assuming that global drug behemoth Pfizer’s and US drug developer Medivation's Dimebon (dimebolin hydrochloride) - an over-the-counter Russian antihistamine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
